

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U.S. Patent No.: 7,235,576 B1

Serial No. : 10/042,203

Filed : January 11, 2002

Issued : June 26, 2007

For : OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS  
RAF KINASE INHIBITORS

**RESUBMISSION OF  
PETITION FOR CERTIFICATE OF CORRECTION  
PURSUANT TO 37 C.F.R. § 1.322 OR § 1.323**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Certificate of Correction filed July 23, 2007 was submitted with 9 pages of corrections. Only 1 page of these corrections have been issued. Applicants hereby resubmit the Certificate of Correction in its entirety and request that the full 9 pages of corrections be reexamined.

C.F.R. § 1.322

☒ The mistakes were incurred through the fault of the Patent and Trademark Office and are clearly disclosed in the records of the Office. Therefore, no fee is due.

Accordingly, patentees and their assignee respectfully request that the Patent and Trademark Office issue a Certificate of Correction pursuant to 37 C.F.R. § 1.322 or § 1.323, respectively.

Respectfully submitted,  
/Richard J. Traverso/

---

Richard J. Traverso, Reg. No. 30,595  
Attorney for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410  
**Attorney Docket No.: BAYER-0025-A**  
**Date: November 25, 2008**

## UNITED STATES PATENT AND TRADEMARK OFFICE

# CERTIFICATE OF CORRECTION

PATENT NO : 7,235,576 B1

DATED : June 26, 2007

INVENTOR(S) : Riedl et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In column 3, line 31, reads "(CH<sub>2</sub>)<sub>m</sub>-and", should read -- (CH<sub>2</sub>)<sub>m</sub>, and --.

In column 4, line 37, reads "methanesulphonic, should read -- methanesulfonic --.

In column 9, line 27, reads "ie.," should read -- i.e., --.

In column 9, line 39, reads "enclosure", should read -- disclosure --.

In column 17, line 1, reads "under stream", should read -- under a stream --.

In column 18, lines 39 and 40, reads "Aromatic", should read -- Aromatic --.

In column 20, line 29, reads "Methylcarbamoly)", should read -- Methylcarbamoyl --.

In column 21, line 27, reads "(N-methylcarbamoly)", should read -- (N-Methylcarbamoyl) --.

In column 21, line 38, reads "(N-methylcarbamoly)", should read -- (N-Methylcarbamoyl) --.

In column 23, line 62, reads "then mixture", should read -- then the mixture --.

In column 30, line 4, reads "(4-(4-Methylsulfonylphenyloxy)", should read -- (4-(4-Methylsulfonylphenoxy) --.

In column 35, line 58, reads "heat", should read -- heated --.

In column 36, line 44, reads "ω-(Aroylamino)phenyl", should read -- ω-(Arylamino)phenyl --.

In column 42, line 29, reads "(triflouromethyl)", should read -- trifluoromethyl --.

MAILING ADDRESS OF SENDER: Millen, White, Zelano & Branigan, P.C.  
2200 Clarendon Blvd. Suite 1400  
Arlington, Va. 22201

PATENT NO. 7,235,576 B1



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.: 7,235,576 B1

DATED: June 26, 2007

INVENTOR(S): Riedl et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In columns 92-98, replace claims 2-47 with the claims 2-17 as follows:

2. A pharmaceutically acceptable salt of claim 1, which is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

3. A pharmaceutically acceptable salt of claim 1 which is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

4. A pharmaceutically acceptable salt which is the tosylate salt of

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl) phenoxy) phenyl) urea,  
*N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl)  
urea,

*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea,


*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl)  
urea; or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)


phenyl) urea.

5. A pharmaceutically acceptable salt of a compound which is:


*N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:



*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:




*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:



; or


*N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




6. A pharmaceutically acceptable salt of claim 5 which is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

7. A pharmaceutically acceptable salt which is the tosylate salt of


*N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:



*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:




*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




; or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




8. A pharmaceutically acceptable salt of a compound which is:

*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:




*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




; or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




**9.** A pharmaceutically acceptable salt of claim 8 which is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.


**10.** A pharmaceutically acceptable salt which is the tosylate salt of  
*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:




*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




*N*-(2-methoxy-4-chloro-5-(trifluoromethyl) phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




**11.** A pharmaceutically acceptable salt of a compound which is:  
*N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:



*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:




*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




**12.** A pharmaceutically acceptable salt of claim 11 which is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

**13.** A pharmaceutically acceptable salt which is the tosylate salt of  
*N*-(2-methoxy-5-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:






*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:




, or

*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula




**14.** A pharmaceutically acceptable salt of a compound which is:

*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:



or


*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:




**15.** A pharmaceutically acceptable salt of claim 14 which is a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

**16.** A pharmaceutically acceptable salt which is the tosylate salt of

*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:



*N*-(4-chloro-3-(trifluoromethyl) phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula



**17.** A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 and pharmaceutically acceptable carrier.